Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. Keeping that in mind, here are three stocks where Wall Street’s enthusiasm may be misplaced and some other investments worth exploring instead.
Gibraltar (ROCK)
Consensus Price Target: $72 (69.7% implied return)
Gibraltar (NASDAQ: ROCK) makes renewable energy, agriculture technology and infrastructure products. Its mission statement is to make everyday living more sustainable.
Why Do We Avoid ROCK?
- Sales tumbled by 9.2% annually over the last two years, showing market trends are working against its favor during this cycle
- Competitive supply chain dynamics and steep production costs are reflected in its low gross margin of 25.6%
- Earnings per share have contracted by 1.6% annually over the last two years, a headwind for returns as stock prices often echo long-term EPS performance
Gibraltar is trading at $42.44 per share, or 11.2x forward P/E. If you’re considering ROCK for your portfolio, see our FREE research report to learn more.
PacBio (PACB)
Consensus Price Target: $2.43 (91.1% implied return)
Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ: PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness.
Why Does PACB Fall Short?
- Annual sales declines of 10.7% for the past two years show its products and services struggled to connect with the market during this cycle
- Cash burn makes us question whether it can achieve sustainable long-term growth
- Negative EBITDA restricts its access to capital and increases the probability of shareholder dilution if things turn unexpectedly
At $1.27 per share, PacBio trades at 2.3x forward price-to-sales. Check out our free in-depth research report to learn more about why PACB doesn’t pass our bar.
Goodyear (GT)
Consensus Price Target: $9.76 (37.7% implied return)
With its iconic blimp floating above major sporting events since 1925, Goodyear (NYSE: GT) is one of the world's largest tire manufacturers, producing and selling tires for automobiles, trucks, aircraft, and other vehicles, along with related services.
Why Are We Cautious About GT?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 4.8% annually over the last two years
- Cash-burning tendencies make us wonder if it can sustainably generate shareholder value
- Below-average returns on capital indicate management struggled to find compelling investment opportunities, and its decreasing returns suggest its historical profit centers are aging
Goodyear’s stock price of $7.09 implies a valuation ratio of 14.5x forward P/E. Dive into our free research report to see why there are better opportunities than GT.
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
